TNX-1900

Tonix Pharmaceuticals, Inc. · Phase 2 active Small molecule

At a glance

Generic name	TNX-1900
Also known as	intranasal oxytocin
Sponsor	Tonix Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder (PHASE2)
A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine (PHASE2)
A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TNX-1900 CI brief — competitive landscape report
TNX-1900 updates RSS · CI watch RSS
Tonix Pharmaceuticals, Inc. portfolio CI